Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Payables (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Payables for 13 consecutive years, with $10.8 million as the latest value for Q4 2025.

  • Quarterly Payables rose 26.62% to $10.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.8 million through Dec 2025, up 26.62% year-over-year, with the annual reading at $10.8 million for FY2025, 26.62% up from the prior year.
  • Payables for Q4 2025 was $10.8 million at Niagen Bioscience, down from $12.7 million in the prior quarter.
  • The five-year high for Payables was $13.7 million in Q2 2025, with the low at $6.9 million in Q3 2024.
  • Average Payables over 5 years is $9.9 million, with a median of $10.0 million recorded in 2021.
  • The sharpest move saw Payables dropped 24.95% in 2024, then soared 84.59% in 2025.
  • Over 5 years, Payables stood at $10.4 million in 2021, then decreased by 7.14% to $9.7 million in 2022, then grew by 5.71% to $10.2 million in 2023, then dropped by 16.67% to $8.5 million in 2024, then rose by 26.62% to $10.8 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $10.8 million, $12.7 million, and $13.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.